Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEW STRAT trial for hospitalized patients with HIV-associated disseminated tuberculosis
PACTR202410837227269Phase 3Recruiting
- Sponsor
- University of Cape Town
- Start
- Aug 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rifampicin, levofloxacin and prednisone in Tuberculosis (TB) and human immunodeficiency virus infection (HIV) (2 arms), sponsored by University of Cape Town. Primary endpoint: All-cause mortality at 12 weeks. Started Aug 2021; status: recruiting.
02
Drugs
rifampicinlevofloxacinprednisone
03
Conditions
Tuberculosis (TB)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on PACTR202410837227269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202410837227269.